The treatment and prevention of coronary heart disease in Canada: Do older patients receive efficacious therapies?

Journal of the American Geriatrics Society

Volumn 47, Issue 7, 1999, Pages 811-818

  McAlister, Finlay A ^a,d   Taylor, Laurel ^a,b   Teo, Koon K ^a,b   Tsuyuki, Ross T ^a,b,c   Ackman, Margaret L ^a,b   Montague, Tenencej ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^d UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

Myocardial infarction; Older; Review; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRINOLYTIC AGENT; STATIN;

AGED; ARTICLE; CANADA; COMMUNITY HOSPITAL; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE QUALITY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; TEACHING HOSPITAL;

EID: 0032770753     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1999.tb03837.x     Document Type: Article

References (74)

1. Hunink MGM, Goldman L, Tosteson ANA et al. The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA 1997;277:535-542.
2. McGovern PG, Pankow JS, Shahar E et al. Recent trends in acute coronary heart disease. Mortality, morbidity, medical care, and risk factors. N Engl J Med 1996;334:884-890.
3. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardia! infarction. JAMA 1988;260:2088-2093.
4. Montague T, Sidel J, Erhardt B et al. Patient health management: A promising paradigm in Canadian Healthcare. Am J Managed Care 1997;3:1175-1182.
5. Anderson JL. Medical therapy for elderly patients who have had myocardial infarction: Too little to the late in life? Ann Intern Med 1996;124:335-338.
6. Gurwitz JH, Gore JM, Goldberg RJ et al. Recent age-related trends in the use of thrombolytic therapy in patients who have had acute myocardial infarction. Ann Intern Med 1996;124:283-291.
7. Krumholz HM, Radford MJ, Ellerbeck EF et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: Prescribed use and outcomes. Ann Intern Med 1996;124:292-298.
8. Pfeffer MA, Moye LA, Braunwald E et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. JAMA 1991;266:528-532.
9. Chandra H, Yarzebski J, Goldberg RJ et al. Age-related trends (1986-1993) in the use of thrombolytic agents in patients with acute myocardial infarction. The Worcester Heart Attack Study. Arch Intern Med 1997;157:741-746.
10. European Secondary Prevention Study Group. Translation of clinical trials into practice: A European population-based study of the use of thrombolysis for acute myocardial infarction. Lancet 1996;347:1203-1207.
11. Gurwitz JH, Goldberg RJ, Chen Z et al. Beta-blocker therapy in acute myocardial infarction: Evidence for underutilization in the elderly. Am J Med 1992;93:605-610.
12. Soumerai SB, McLaughlin TJ, Spiegelman D et al. Adverse outcomes of underuse of β-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-121.
13. McLaughlin TJ, Soumerai SB, Willison DJ et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction. Arch Intern Med 1996;156:799-805.
14. Rogers WJ, Bowlby LJ, Chandra NC et al. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994;90:2103-2114.
15. Krumholz HM, Murillo JE, Chen J et al. Thrombolytic therapy for eligible elderly patients with acute myocardial infarction. JAMA 1997;277:1683-1688.
16. Krumholz HM, Radford MJ, Wang Y et al. National use and effectiveness of β-blockers for the treatment of elderly patients after acute myocardial infarction. National Cooperative Cardiovascular Project. JAMA 1998;280:623-629.
17. Fibrinolytic Therapy Trialists Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994:343:311-322.
18. Baigent C, Collins R. ISIS-2:4-year mortality follow up of 17,817 patients after fibrinolytic and antiplatelet therapy in suspected acute myocardial infarction Circulation 1993;88(suppl):I-291.
19. Gurwitz JH, Gore JM, Goldberg RJ et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Ann Intern Med 1998;129:597-604.
20. Arnold AER, Simoons ML. Thrombolytic therapy for evolving myocardial infarction needs an approach that integrates benefit and risk. Eur Heart J 1995;16:1502-1509.
21. Krumholz HM, Pasternak RC, Weinstein MC et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992;327:7-13.
22. Naylor CD, Bronskill S, Goel V. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction. Can J Cardiol 1993;9:553-558.
23. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
24. Mark DB, Hlatky JA, Califf RM et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-1424.
25. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
26. Tsuyuki RT, Teo KK, Ikuta RM et al. Mortality risk and patterns of practice in 2070 patients with acute myocardial infarction 1987-92. The relative importance of age, sex and medical therapy. Chest 1994;105:1687-1692.
27. Deedwania PC, Amsterdam EA, Vagelos RH, for the California Cardiology Working Group on Post-Mi Management. Evidence-based, cost-effective risk stratification and management after myocardial infarction. Arch Intern Med 1997;157:273-280.
28. McAlister FA, Teo KK. Antiarrhythmic therapies for the prevention of sudden cardiac death. Drugs 1997;54:235-252.
29. The Bcta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): Subgroup findings from randomized trials in post-infarction patients. Eur Heart J 1988;9:8-16.
30. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;ii:57-66.
31. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled internatipnal trial. Eur Heart J 198;6:199-226.
32. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blocka'de on mortality among high-risk and low-risk patients after myocardial infarction. N Engl JMed 1998;339:489-497.
33. Goldman L, Sia STB, Cook EF et al. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. N Engl J Med 1988;319:152-157.
34. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-373.
35. Montague T, Tsuyuki R, Burton J et al. Prevention and regression of coronary atherosclerosis: Is it safe and efficacious therapy? Chest 1994;105:718-26.
36. Corti MC, Guralnik JM, Salive ME et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med 1997;126:753-760.
37. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
38. Miettinen TA, Pyorala K, OIsson AG et al. for the Scandinavian Simvastatin Survival Study Group. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Circulation 1997;96: 4211-4218.
39. Lewis SJ, Moye LA, Sacks FM et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Ann Intern Med 1998;129:681-689.
40. The Long-term Intervention with Pravastatin in Ischaemic heart Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
41. Johannesson M, Jonsson B, Kjekshus J et al.for the Scandinavian Simvastatin Survival Study Group. Cost effectiveness of Simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997;336:332-336.
42. The Clinical Quality Improvement Network (CQIN) Investigators. Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly. Am J Cardiol 1995;76:570-573.
43. The Clinical Quality Improvement Network (CQIN) Investigators. Cardiovascular risk management among 1806 low risk patients in a primary care setting. Can J Cardiol 1996;12:797-801.
44. The Clinical Quality Improvement Network (CQIN) Investigators. Mortality risk and patterns of practice in 4,606 acute care patients with congestive heart failure. The relative importance of age, sex and medical therapy. Arch Intern Med 1996;156:1669-1673.
45. The CQIN Investigators. Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. Can J Cardiol 1998;14:695-702.
46. McAlister F, Teo KK, Lewanczuk R et al. Contemporary practice patterns in the management of newly diagnosed hypertensive patients. Can Med Assoc J 1997;157:23-30.
47. McAlister F, Laupacis A, Teo KK et al. A survey of clinician attitudes and management practices in hypertension. J Hum Hypertens 1997;11:413-419.
48. McAlister FA, Teo KK, Laupacis A. A survey of management practices for isolated systolic hypertension. J Am Geriatr Soc 1997;45:1219-1222.
49. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273: 1450-1456.
50. Joffres MR, Hamet P, Rabkin SW et al. for the Canadian Heart Health Surveys Research Group. Prevalence, control and awareness of high blood pressure among Canadian adults. Can Med Assoc J 1992;146:1997-2005.
51. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA 1992;268:1460-1467.
52. Avorn J. Benefit and cost analysis in geriatric care: Turning age discrimination into health policy. N Engl J Med 1984;310:1294-1301.
53. Welch HG, Albertsen PC, Nease RF et al. Estimating treatment benefits for the elderly: The effect of competing risks. Ann Intern Med 1996;124:577-584.
54. Guralnik JM, Land KC, Blazer D et al. Educational status and active life expectancy among older blacks and whites. N Engl J Med 1993;329:110-116.
55. Cox JL, Lee E, Langer A et al. for the Canadian GUSTO Investigators. Time to treatment with thrombolytic therapy: Determinants and effect on shortterm nonfatal outcomes of acute myocardial infarction. Can Med Assoc J 1997;156:497-505.
56. Weaver WD, Litwin PE, Martin JS et al. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. J Am Coll Cardiol 1991;18:657-662.
57. Krumholz HM, Friesinger GC, Cook EF et al. Relationship of age with eligibility for thrombolytic therapy and mortality among patients with suspected acute myocardial infarction. J Am Geriatr Soc 1994;42:127-131.
58. Nadelmann J, Frishman WH, Ooi WL et al. Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years or older: The Bronx Aging Study. Am J Cardiol 1990;66:533-537.
59. Ellerbeck EF, Jencks SF, Radford MJ et al. Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovacular Project. JAMA 1995;273:1509-1514.
60. Meyer JW, Rowan B. Institutional organizations: Formal structure as myth and ceremony. Am J Sociol 1977;83:340-363.
61. Teo KK, Minings CR, Naylor D et al. Protocol to confirm, and determine the causation of, age and sex biases in the contemporary management of patients with AMI. Medical Research Council and Merck Frosst Canada Inc. Ottawa, Ontario, and Kirkland, Quebec, Canada, June, 1997.
62. Montague T, Taylor L, Barnes M et al. for the Clinical Quality Improvement Network (CQIN) Investigators. Can practice patterns be successfully altered? Examples from cardiovascular medicine. Can J Cardiol 1995;11:487-492.
63. Gurwitz JH, Goldberg RJ, Chen Z et al. Recent trends in hospital mortality of acute myocardial infarction -the Worcester Heart Attack Study. Have improvements been realized for all age groups? Arch Intern Med 1994;154: 2202-2208.
64. Oxman AD, Thomson MA, Davis DA, Haynes RB. No magic bullets: A systematic review of 102 trials of interventions to improve professional practice. Can Med Assoc J 1995;153:1423-1431.
65. Col NF, McLaughlin TJ, Soumerai SB et al. The impact of clinical trials on the use of medications for acute myocardial infarction. Results of a community-based study. Arch Intern Med 1996;156:54-60.
66. The Clinical Quality Improvement Network (CQIN) Investigators. Influence of a critical path management tool in the treatment of acute myocardial infarction. Am J Managed Care 1998; 4:1243-1251.
67. Worrall G, Chaulk P, Freake D. The effects of clinical practice guidelines on patient outcomes in primary care: A systematic review. Can Med Assoc J 1997;156:1705-1712.
68. Grimshaw JM, Russell IT: Effect of clinical guidelines on medical practice: A systematic review of rigorous evaluations. Lancet 1993;342:1317-1322.
69. Hux JE, Naylor CD. When knowing enough is not enough. Can J Cardiol 1997;13:1160-1161.
70. Soumerai SB, McLaughlin TJ, Gurwitz JH et al. Effect of local medical opinion leaders on quality of care for acute myocardial infarction. A randomized controlled trial. JAMA 1998;279:1358-1363.
71. O'Connor AM. Consumer/patient decision support in the new millenium: Where should our research take us? Can J Nurs Res 1997;29:7-12.
72. Tsuyuki RT, Johnson JA, Teo KK et al for the SCRIP Investigators. Design of the study of cardiac risk intervention by pharmacists (SCRIP): A study of the effect of community pharmacist identification, assessment, and intervention on cardiac risk factor modification practices. Can J Clin Pharmacol (abstract) 1998;5:68.
73. Tugwell P, Bennett KJ, Sackett DL, Haynes RB. The measurement iterative loop: A framework for the critical appraisal of need, benefits, and costs of health interventions. J Chronic Dis 1985;38:339-351.
74. The Royal Pharmaceutical Society of Great Britain Working Party on Partnership in Medicine Taking. From Compliance to Concordance: Achieving Shared Goals in Medicine Taking. London: The Royal Pharmaceutical Society Of Great Britain, March, 1997.